Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines

Inclusion Criteria: * moderate to severe glabellar frown lines at maximum frown ((severity score of 2 or 3 on Facial Wrinkle Scale(FWS)as assessed by the investigator's rating: 0 = 'none', 1 = 'mild', 2 = 'moderate', 3 = 'severe' * Stable medical condition * Age: between 18 and 65 years (inclusively) Exclusion Criteria: * Previous treatment with Botulinum toxin of any serotype in the upper third part of the face within the last 6 month * Previous treatment with biodegradable fillers in the glabellar area within the last 12 month * Previous insertion of permanent material in the glabellar area, including fat graft (regardless of the time between previous treatment and this study) * Any surgery in the glabellar area including surgical removal of the corrugator, procerus, or depressor supercilii muscles or a combination of these, or scars in the glabellar area * Any other planned cosmetic procedure in the upper third part of the face during the trial period * Inability to substantially lessen glabellar frown lines even by physically spreading them apart * Marked facial asymmetry or ptosis of eyelid and/or eyebrow * History of facial nerve palsy * Any infection in the area of the injection sites